{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T17:07:51Z","timestamp":1788541671191,"version":"build-2803163510"},"reference-count":32,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T00:00:00Z","timestamp":1644883200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Reports"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Relapsed refractory multiple myeloma (RRMM) is a disease that is nonresponsive or progressive on therapy, and although patients can achieve remission, relapse is common. As more treatment options become available for multiple myeloma (MM), it is important to understand patients' experiences of current and emerging therapies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aims<\/jats:title><jats:p>This study aimed to better understand patient experiences with treatment and therapies for MM using qualitative interviews and patient\u2010reported information (PRI) shared on social media.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Semistructured qualitative interviews were conducted with adults with RRMM who resided in the United States. In addition to the interviews, PRI was collected from YouTube and a patient advocacy website. Key themes from the interviews and PRI were summarized, and illustrative quotes were extracted.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Twenty participants were interviewed; 11 were female, and mean (standard deviation) age was 60 (7.0) years. The PRI included 14 posts and 19 unique contributors (10 were female). Similar treatment\u2010related symptoms were reported in the interviews and PRI. Fatigue and pain were the most frequently reported symptoms while receiving treatment in both the interviews and PRI. These symptoms had a meaningful impact on health\u2010related quality of life (HRQOL); being off treatment and returning to normal living was described as an ideal treatment outcome. Nearly all interview participants (<jats:italic>n<\/jats:italic>\u00a0=\u00a018) preferred a treatment that would allow for a treatment\u2010free interval, if it had the same efficacy and safety profile as a continuous treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The symptom experience reported in this study is consistent with known RRMM symptoms and HRQOL impacts. Additionally, this study highlighted that patients' treatment expectations are changing relative to their past treatment experience. Individuals living with RRMM strongly desire therapies with a treatment\u2010free interval and minimal impact on their HRQOL.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cnr2.1603","type":"journal-article","created":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T23:39:11Z","timestamp":1644968351000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The patient experience of relapsed refractory multiple myeloma and perspectives on emerging therapies"],"prefix":"10.1002","volume":"5","author":[{"given":"Rebecca","family":"Crawford","sequence":"first","affiliation":[{"name":"RTI Health Solutions  Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharine S.","family":"Gries","sequence":"additional","affiliation":[{"name":"Janssen Global Services, LLC  Raritan NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satish","family":"Valluri","sequence":"additional","affiliation":[{"name":"Janssen Global Services, LLC  Raritan NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Fastenau","sequence":"additional","affiliation":[{"name":"Janssen Global Services, LLC  Raritan NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross","family":"Morrison","sequence":"additional","affiliation":[{"name":"RTI Health Solutions  Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzu\u2010Min","family":"Yeh","sequence":"additional","affiliation":[{"name":"Janssen Global Services, LLC  Raritan NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunsi","family":"Olyslager","sequence":"additional","affiliation":[{"name":"Janssen Global Services, LLC  Raritan NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna D.","family":"Goldberg","sequence":"additional","affiliation":[{"name":"Janssen Global Services, LLC  Raritan NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan M.","family":"Schecter","sequence":"additional","affiliation":[{"name":"Janssen Global Services, LLC  Raritan NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn C.","family":"Jackson","sequence":"additional","affiliation":[{"name":"Janssen Global Services, LLC  Raritan NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Deraedt","sequence":"additional","affiliation":[{"name":"Janssen Global Services, LLC  Raritan NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynda","family":"Doward","sequence":"additional","affiliation":[{"name":"RTI Health Solutions  Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,2,15]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.129189"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2015.11.007"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885\u2010019\u20105467\u2010x"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885\u2010016\u20102410\u20102"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408\u2010021\u201000432\u20104"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019001026"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102020\u2010136383"},{"key":"e_1_2_12_9_1","unstructured":"MartinT LinY AghaM CohenA HtutM StewartK.Health\u2010related quality of life in the Cartitude\u20101 study of ciltacabtagene autoleucel for relapsed\/refractory multiple myeloma. Poster presented at the American Society of Hematology Annual Meeting and Exposition; December 5\u20138 2020; Virtual."},{"key":"e_1_2_12_10_1","unstructured":"Food and Drug Administration.Patient\u2010focused drug development: collecting comprehensive and representative input. Guidence for Industry Food and Drug Administration Staff and Other Stakeholders. US Department of Health and Human Services 2018."},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.2165\/11585530\u2010000000000\u201000000"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916\u2010018\u20101247\u20108"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pec.2013.06.020"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11606\u2010010\u20101526\u20103"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen\u20102015\u2010010501"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2019.09.2281"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/s41687\u2010020\u201000242\u20105"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1191\/1478088706qp063oa"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12874\u2010018\u20100594\u20107"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0232076"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0198606"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0181689"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1177\/1049732315617444"},{"key":"e_1_2_12_24_1","first-page":"39","article-title":"Reflecting on the development of interpretative phenomenological analysis and its contribution to qualitative research in psychology","volume":"1","author":"Smith JA","year":"2004","journal-title":"Qual Res Psychol"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520\u2010013\u20101991\u20104"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2012.11.003"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265\u2010017\u20100841\u2010y"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2017.01.003"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.127860"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136\u2010019\u201002392\u20106"},{"key":"e_1_2_12_31_1","doi-asserted-by":"crossref","unstructured":"KnightJ ArapiI SzaboA et al.Quality of life tryptophan metabolites and neurotoxicity assessments of patients with relapsed or refractory B cell malignancies undergoing CAR 20\/19\u2014T cell therapy. Poster presented at the American Society of Hematology Annual Meeting and Exposition; December 5\u20138 2020; Virtual","DOI":"10.1182\/blood-2020-141703"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.6594"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.4103\/2249\u20104863.161306"}],"container-title":["Cancer Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cnr2.1603","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cnr2.1603","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cnr2.1603","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T01:43:21Z","timestamp":1692668601000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cnr2.1603"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,15]]},"references-count":32,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["10.1002\/cnr2.1603"],"URL":"https:\/\/doi.org\/10.1002\/cnr2.1603","archive":["Portico"],"relation":{},"ISSN":["2573-8348","2573-8348"],"issn-type":[{"value":"2573-8348","type":"print"},{"value":"2573-8348","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,15]]},"assertion":[{"value":"2021-08-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-15","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e1603"}}